Singapore Startup Bioactivx Secures $3 Million to Advance Synthetic Skin Technology
A Singapore-based deep-tech startup, Bioactivx, has successfully raised $3 million in a pre-Series A funding round. The company is currently focused on developing innovative synthetic materials designed for advanced wound care.
This significant investment highlights the growing importance of medical technology within Singapore’s startup ecosystem. By creating synthetic skin substitutes, Bioactivx aims to provide better treatment options for patients suffering from complex wounds that are difficult to heal.
The capital raised will be used to support the company’s research and development efforts. As the startup continues to refine its technology, it hopes to bring its medical solutions to the broader healthcare market, potentially improving recovery outcomes for many people.
This development is a positive sign for Singapore’s position as a hub for biotechnology and scientific innovation. As Bioactivx moves forward with its plans, the medical community will be watching closely to see how this new technology performs in future clinical applications.